SAT0655 THE SPECTRUM OF MYOSITIS ANTIBODIES: CLINICAL CORRELATION AND PREVALENCE OF ANTI-DFS70
| Autor: | Antonio Carriero, Angela Padula, Carmela Esposito, Salvatore D'Angelo, Vito Pafundi, Maria Carmela Padula, V. Picerno, Teresa Carbone |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
education.field_of_study
medicine.medical_specialty business.industry Population Interstitial lung disease Undifferentiated connective tissue disease Antisynthetase syndrome Overlap syndrome Dermatomyositis medicine.disease Polymyositis Gastroenterology Internal medicine medicine education business Myositis |
| Zdroj: | Saturday, 15 June 2019. |
| Popis: | Background: Myositis can be a clinical feature of several rheumatic diseases. In inflammatory idiopathic myopathies (IIM), such as Dermatomyositis (DM), Polymyositis (PM), Antisynthetase syndrome (ASS), muscular lesions are immune-mediated and may associate with skin, aesophagus, lung, heart and joint involvement. The role of myositis specific antibodies (MSA) and myositis associated antibodies (MAA) in determining the clinical phenotype is still unclear. Anti-dense fine speckled antibodies (anti-DFS70ab) show a low frequency in DM and are generally associated with DM-specific autoantibodies Objectives: to characterize antibodies in IIM and myositis related to other rheumatic diseases and to correlate them to clinical features, cancer history and anti-DFS70ab presence. Methods: 37 patients with myositis (including IIM, overlap syndrome and myositis related to other rheumatic diseases) were evaluated. Anti-DFS70ab pattern was determined by indirect immunofluorescence on HEp-2000 cells. Detection of anti-DFS70ab specificity (truncated sequence of the DFS70 antigen (residues 349-435)), of MSA (MDA-5, TIF 1-γ, SAE1, SAE2, NXP-2, Jo-1, PL-7, PL-12, EJ, OJ, KS, ZO, HA, SRP, Mi-2,), of MAA (U1-RNP, SSaRo52/60, PM-Scl100/75, Ku) and of other Scleroderma associated antibodies (Scl-70, CENP-A, CENP-B, RNA Polymerase III, Th/to, Fibrillarin) were performed using immunoblotting assay. Clinical, serological and instrumental data were recorded. Results: 15 patients had a diagnosis of DM, 8 of PM, 3 of ASS, 5 of overlap syndrome (3 with Systemic Sclerosis (SSc), 1 with Sjogren Syndrome (SS), 1 with cryoglobulinemia), 6 of myositis related to other rheumatic disease (1 SSc, 1 Rheumatoid Arthritis, 2 Undifferentiated Connective Tissue Disease, 2 Systemic Lupus Erithematosus). In IIM, overall frequencies of MSA and MAA were 46.1% (12/26) and 38.4% (10/26), respectively, with concomitant expression in 5/26 cases. The 30.7% (8/26) of patients was negative for any type of antibodies. Mi-2 (4/15=26.6%), NXP-2 (3/15=20%) and SRP (2/15=15.3%) were detected in DM subset and were associated with typical skin lesions, muscle weakness, dysphagia and microvascular damage on capillaroscopy, while no interstitial lung disease, cardiac and articular involvement were recorded. Jo-1 was positive in 5/26 patients (2 PM, 2 ASS, 1 DM=19.2%) characterized by interstitial lung disease, arthritis, skin involvement and muscle weakness and by pulmonary hypertension when associated with TIF1- γ (1 DM=6.6%). Autoantibodies profile in overlap syndrome and myositis related to other rheumatic diseases was characterized by prevalence of MAA, more frequently PM-Scl100/75, RNP, Ku, SSaRo52/60. Only in 1 patient with an overlap syndrome SSc/PM HMGCR reactivity was detected. As far as cancer association, a positive history was found in 8.1% (3/37), related more frequently to Jo-1 and SSaRo52. Anti-DFS70ab were positive in 2/26 patients with IIM (7.6%; 1 DM and 1 PM) and in 1 with SSaRo60. No cases of anti-DFS70ab positivity was found in other subsets. Conclusion: Prevalence of MSA and MAA and their clinical correlations in our population are comparable to data reported in literature. Mi-2, NXP-2 and SRP can be considered markers of DM, while Jo-1 a predictor of lung involvement. Jo1/SSaRo52 positivity is reported in association with lung cancer, but to our knowledge no data are present about melanoma. Our preliminary data confirm that, not only in DM but also in PM, anti-DFS70ab were observed with a low frequency; however more studies are needed to establish the pathogenetic role of these antibodies. Disclosure of Interests: carmela esposito: None declared, Teresa Carbone: None declared, Antonio Carriero: None declared, valentina picerno: None declared, Maria Carmela Padula: None declared, Angela Padula Speakers bureau: Lilly Italia EMS, vito pafundi: None declared, Salvatore D’Angelo: None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|